2026-06-14T05:05:20Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/199552024-11-28T20:30:43Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud
author
Gutierrez, Antonio
author
Rodriguez, Jose
author
Martinez-Serra, Jordi
author
Gines, Jordi
author
Paredes, Pilar
author
Garcia, Florencia
author
Vercher, Javier
author
Balanzat, Josep
author
del Campo Garcia, Raquel
author
Galan, Pilar
author
Morey, Miguel
author
Sampol Mayol, Antonia
author
Novo, Andrés
author
Bento, Leyre
author
Garcia, Lucia
author
Bargay Lleonart, Joan
author
Besalduch Vidal, Juan
2024-07-03T11:01:17Z
2024-07-03T11:01:17Z
2014
Gutierrez A, Rodriguez J, Martinez Serra JJ, Gines J, Paredes P, Garcia F, et al. Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. OncoTargets Ther. 2014;7:2093-100.
10.2147/OTT.S70264
1178-6930
Oncotargets and Therapy
http://hdl.handle.net/20.500.13003/17195
25419147
L600435312
2-s2.0-84910683675
http://hdl.handle.net/20.500.12105/19955
344932400001
Background: Most Hodgkin lymphomas (HL) can be cured with current strategies. However, one-third of the cases do not respond or relapse and need salvage regimens. We report the results of a retrospective study using the gemcitabine and oxaliplatinum (GemOx) regimen. Methods: Patients who relapsed or failed to achieve complete response were eligible and received GemOx salvage therapy. To avoid selection bias and thus to overcome the retrospective nature of the study, all treated patients were included from the pharmacy database. Results: Between 2003-2013, 24 HL patients - relapsing (number [n]=12) or refractory (n=12) - were included, receiving a total of 26 induction treatments with GemOx. Mean previous regimens were 2.38 (42% relapsing after autologous transplantation). Median follow-up was 37 months, and 71% responded (38% of patients achieved complete response). The factors related to better progression-free survival were: B symptoms; response to GemOx; and consolidation with stem cell transplantation. Grades 1 and 2 neurological toxicity was present in 17% of patients. Hematological toxicity was common, with grades 3 and 4 neutropenia (25%) and thrombocytopenia (34%) observed. Progression-free survival was better in patients consolidated with stem cell transplantation. The peripheral blood stem cell collection after GemOx was successful for all candidates. Conclusion: 1) The GemOx regimen is effective in relapsed or refractory HL with manageable toxicity. 2) No mobilization failures were observed. 3) Consolidation after response is needed. 4) Its efficacy and favorable toxicity profile might make multiple administrations possible in several recurrences in HL.
eng
Gemcitabine
Oxaliplatinum
GemOx
Hodgkin lymphoma
Treatment
Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma
research article